Core Viewpoint - Credit Lyonnais has raised JD Health's (06618) adjusted net profit forecasts for the fiscal years 2026 and 2027 by 1% and 2% respectively, reflecting the recovery in drug sales and profit expansion prospects, while maintaining an "Outperform" rating and a target price of HKD 71 [1] Group 1: Financial Performance - JD Health is expected to maintain growth momentum in the second half of last year, driven by strong performance during the Double Eleven sales event and a surge in flu cases in December, with revenue projected to increase by 24.5% year-on-year to RMB 37.1 billion [1] - The company is anticipated to see adjusted EBIT double year-on-year to RMB 2.1 billion, supported by gross margin expansion and operational leverage [1] - Revenue for 2026 is expected to grow by 16% year-on-year [1]

Core Viewpoint - Morgan Stanley has raised the target price for JD Health from HKD 60 to HKD 68.8, maintaining a "Market Perform" rating, reflecting positive adjustments based on the company's third-quarter performance [1] Financial Performance - The increase in target price is attributed to growth in direct sales and service revenue, leading to an upward revision of total revenue forecasts for the years 2025 to 2027 by 1.4% [1] - The expansion of drug sales and an increase in the proportion of advertising revenue are expected to enhance the company's gross margin [1] - The forecast for recurring earnings per share has been raised by 9%, 13%, and 13% for the respective years 2025, 2026, and 2027 [1]

Core Viewpoint - The report from Credit Lyonnais indicates that JD Health's performance in the first half of the year met expectations, driven by strong user growth and good performance during the 618 shopping festival [1] Financial Performance - JD Health's revenue increased by 24.5% year-on-year to 35.3 billion yuan [1] - Earnings before interest and taxes (EBIT) rose by 57% year-on-year to 2.5 billion yuan [1] Market Trends - There has been a shift in demand for original research drugs from hospitals to outpatient settings, contributing to an increase in drug sales [1] Future Outlook - Credit Lyonnais raised JD Health's net profit forecasts for 2025 and 2026 by 15% and 13% respectively [1] - The target price for JD Health was increased from 56 HKD to 64 HKD, maintaining an "outperform" rating [1]